Company Analysis
Sign in

Bolt Biotherapeutics, Inc. (BOLT)

Nasdaq: BOLT · Pharmaceutical Preparations · Redwood City, CA · filing with the SEC since 2015
Full chart Alerts Compare
Grade4.8
◀ Past 6.8● Present 4.5▶ Future 3.7
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

8 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Bolt Biotherapeutics, Inc.’s names, not what it holds today.

Patents granted
8
8 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against none in 2024 and 3 in 2023
Applications published
44
6 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals5
Biotechnology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
BOLT BIOTHERAPEUTICS, INC. its own name
US, as the owner printed on each patent
8 granted
41 published
BOLT BIOTHERAPEUTICS, INC. its own name
named as the applicant on its applications, in US
0 granted
3 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 11, 202512,465,653Thienoazepine immunoconjugates, and uses thereofPharmaceuticalsBOLT BIOTHERAPEUTICS, INC.
Jun 10, 202512,325,750Anti-Dectin-2 antibodies and methods of usingBiotechnologyBOLT BIOTHERAPEUTICS, INC.
Sep 12, 202311,753,474Anti-Dectin-2 antibodiesBiotechnologyBOLT BIOTHERAPEUTICS, INC.
May 23, 202311,654,199Thienoazepine immunoconjugates, and uses thereofPharmaceuticalsBOLT BIOTHERAPEUTICS, INC.
Jan 10, 202311,547,761Antibody adjuvant conjugatesPharmaceuticalsBOLT BIOTHERAPEUTICS, INC.
Aug 2, 202211,400,164Immunoconjugates targeting HER2PharmaceuticalsBOLT BIOTHERAPEUTICS, INC.
Sep 7, 202111,110,178Antibody adjuvant conjugatesPharmaceuticalsBOLT BIOTHERAPEUTICS, INC.
Jun 9, 202010,675,358Antibody adjuvant conjugatesPharmaceuticalsBOLT BIOTHERAPEUTICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Aug 28, 20252025/0270329Anti-Dectin-2 AntibodiesBiotechnologyBOLT BIOTHERAPEUTICS, INC.
Aug 21, 20252025/0263392AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOFOrganic fine chemistryBOLT BIOTHERAPEUTICS, INC.
May 8, 20252025/0145575MACROMOLECULE-SUPPORTED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USESOrganic fine chemistryBOLT BIOTHERAPEUTICS, INC.
Apr 24, 20252025/0127914ANTIBODY-CONJUGATED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USESPharmaceuticalsBOLT BIOTHERAPEUTICS, INC.
Feb 20, 20252025/0057967BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES, AND USES THEREOFPharmaceuticalsBOLT BIOTHERAPEUTICS, INC.
Jan 2, 20252025/0000995TLR AGONIST IMMUNOCONJUGATES WITH CYSTEINE-MUTANT ANTIBODIES, AND USES THEREOFPharmaceuticalsBOLT BIOTHERAPEUTICS, INC.
Dec 19, 20242024/0417486ASYMMETRIC BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES AND USES THEREOFPharmaceuticalsBOLT BIOTHERAPEUTICS, INC.
Oct 10, 20242024/0335557BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES, AND USES THEREOFPharmaceuticalsBOLT BIOTHERAPEUTICS, INC.
Sep 12, 20242024/02995692-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOFPharmaceuticalsBOLT BIOTHERAPEUTICS, INC.
Jul 18, 20242024/0238430ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOFPharmaceuticalsBOLT BIOTHERAPEUTICS, INC.
What it applied for, 2024 to 2025: Pharmaceuticals 11 · Organic fine chemistry 2 · Biotechnology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton BOLT · research, not advice